Business
Todos Medical to Appoint Dr. Paula Trzepacz As Chief Medical Officer And Files New Patent Application
Todos Medical to Appoint Dr. Paula Trzepacz As Chief Medical Officer And Files New Patent Application.
About this update from Amarantus Bioscience Holdings, Inc.
[{"type":"text","content":"\nJoint venture Breakthrough Diagnostics files new patent application covering Alzheimer’s blood diagnostic LymPro Test clinical correlation with amyloid PET imagingPreliminary Data on LymPro vs. amyloid PET to be released during AAIC 2019 REHOVOT, Israel, July 12, 2019 (GLOBE NEWSWIRE) -- Todos Medical Ltd. (OTCQB: TOMDF), a clinical-stage in-vitro diagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders, such as Alzheimer's disease, today announced the appointment of Dr. Paula Trzepacz as Chief Medical Officer of Breakthrough Diagnostics, Inc. Dr. Trzepacz is a geriatric psychiatrist and neuropsychiatrist with extensive experience in the clinical development of therapeutics and diagnostics for Alzheimer’s disease and other neurocognitive disorders. Dr. Trzepacz is currently serving as Medical Advisor to the Company’s joint venture Breakthrough Diagnostics, Inc. (‘Breakthrough’), an entity that Todos is in the process of acquiring from Amarantus Bioscience Holdings, Inc. (OTCPK: AMBS). Concurrent with this announcement, Breakthrough has filed a new patent application covering the Alzheimer’s blood diagnostic LymPro Test’s correlation to amyloid PET imaging. Preliminary data from an ongoing clinical study at Leipzig University related to the patent filing will be released on July 15th, during AAIC 2019.\n \"Dr. Trzepacz brings significant expertise to the Company as a pioneer in the clinical development, regulatory process and commercialization of diagnostic tests for neurodegenerative disease, specifically Alzheimer’s disease\" said Dr. Herman Weiss, CEO of Todos Medical. \"Dr. Trzepacz has extensive experience in dementia and other neurocognitive disorders . Additionally, Dr. Trzepacz served on the global development team for Amyvid, the first FDA approved PET radiotracer indicated for estimation of beta-amyloid plaque density in brains of cognitively impaired persons suspected of having Alzheimer's disease.  Dr. Trzepacz’s knowledge of bringing first-of-its-kind diagnostic assays for Alzheimer’s disease to market will make Paula a tremendous asset to our organization.” \"I am delighted to join Todos Medical at a time when the Company is preparing for the introduction of highly specific ...